122 related articles for article (PubMed ID: 37235970)
21. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
23. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
[TBL] [Abstract][Full Text] [Related]
24. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
25. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
26. Positive intraoperative pleural lavage cytology is a predictive marker of disease recurrence in stage I lung adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Abe M; Watanabe K; Watanabe I; Uematsu M; Ogata SY; Sato T; Tamura G
Interact Cardiovasc Thorac Surg; 2014 May; 18(5):621-5. PubMed ID: 24532312
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of a machine learning algorithm for assessing tumour components as a prognostic marker of surgically resected stage IA lung adenocarcinoma.
Terada Y; Isaka M; Kawata T; Mizuno K; Muramatsu K; Katsumata S; Konno H; Nagata T; Mizuno T; Serizawa M; Ono A; Sugino T; Shimizu K; Ohde Y
Jpn J Clin Oncol; 2023 Jan; 53(2):161-167. PubMed ID: 36461783
[TBL] [Abstract][Full Text] [Related]
28. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
[TBL] [Abstract][Full Text] [Related]
29. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.
Kadota K; Yeh YC; Villena-Vargas J; Cherkassky L; Drill EN; Sima CS; Jones DR; Travis WD; Adusumilli PS
Chest; 2015 Sep; 148(3):711-721. PubMed ID: 25836013
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung cancer surgery.
Ramos R; Macía I; Navarro-Martin A; Déniz C; Rivas F; Ureña A; Masuet-Aumatell C; Moreno C; Nadal E; Escobar I
BMC Pulm Med; 2021 Mar; 21(1):75. PubMed ID: 33653309
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
32. Single-cell spatial landscapes of the lung tumour immune microenvironment.
Sorin M; Rezanejad M; Karimi E; Fiset B; Desharnais L; Perus LJM; Milette S; Yu MW; Maritan SM; Doré S; Pichette É; Enlow W; Gagné A; Wei Y; Orain M; Manem VSK; Rayes R; Siegel PM; Camilleri-Broët S; Fiset PO; Desmeules P; Spicer JD; Quail DF; Joubert P; Walsh LA
Nature; 2023 Feb; 614(7948):548-554. PubMed ID: 36725934
[TBL] [Abstract][Full Text] [Related]
33. Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients.
Di Lorenzo A; Tedde S; Pace PG; Campogiani L; Ansaldo L; Lodi A; Zordan M; Barreca F; Caldara F; Rossi B; Imeneo A; Alessio G; Crea AMA; Checchi D; Malagnino V; Teti E; Coppola L; Palmieri R; Buccisano F; Andreoni M; Sarmati L; Iannetta M
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359306
[TBL] [Abstract][Full Text] [Related]
34. Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas.
Lee HY; Cha MJ; Lee KS; Lee HY; Kwon OJ; Choi JY; Kim HK; Choi YS; Kim J; Shim YM
J Thorac Oncol; 2016 Jul; 11(7):1064-73. PubMed ID: 27016260
[TBL] [Abstract][Full Text] [Related]
35. [Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma].
Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
[TBL] [Abstract][Full Text] [Related]
36. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
37. Prognostic score for survival with pulmonary carcinoids: the importance of associating clinical with pathological characteristics.
Chiappetta M; Sperduti I; Ciavarella LP; Leuzzi G; Bria E; Mucilli F; Lococo F; Filosso P; Ratto G; Spaggiari L; Facciolo F; Margaritora S
Interact Cardiovasc Thorac Surg; 2020 Sep; 31(3):315-323. PubMed ID: 32747930
[TBL] [Abstract][Full Text] [Related]
38. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.
Orhan A; Vogelsang RP; Andersen MB; Madsen MT; Hölmich ER; Raskov H; Gögenur I
Eur J Cancer; 2020 Jun; 132():71-84. PubMed ID: 32334338
[TBL] [Abstract][Full Text] [Related]
40. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
